Therefore, we evaluated 14-3-3 protein as well as CSF levels of tau, phosphotau181 and Aβ1-42 in 127 cases of definite sCJD, 5 subjects with familial CJD (fCJD), 7 patients clinically diagnosed with Alzheimer’s disease (AD), and 15 patients with frontotemporal dementia (FTD). This evidence concerns the gene MAPT and frontotemporal dementia.